129 related articles for article (PubMed ID: 15064018)
1. Cytotoxicity of the bioreductive agent RH1 and its lack of interaction with radiation.
Kim JY; West CM; Valentine H; Ward TH; Patterson AV; Stratford IJ; Roberts SA; Hendry JH
Radiother Oncol; 2004 Mar; 70(3):311-7. PubMed ID: 15064018
[TBL] [Abstract][Full Text] [Related]
2. The importance of DT-diaphorase and hypoxia in the cytotoxicity of RH1 in human breast and non-small cell lung cancer cell lines.
Kim JY; Patterson AV; Stratford IJ; Hendry JH
Anticancer Drugs; 2004 Jan; 15(1):71-7. PubMed ID: 15090746
[TBL] [Abstract][Full Text] [Related]
3. The bioreductive agent RH1 and gamma-irradiation both cause G2/M cell cycle phase arrest and polyploidy in a p53-mutated human breast cancer cell line.
Kim JY; Kim CH; Stratford IJ; Patterson AV; Hendry JH
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):376-85. PubMed ID: 14751506
[TBL] [Abstract][Full Text] [Related]
4. Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1).
Yan C; Kepa JK; Siegel D; Stratford IJ; Ross D
Mol Pharmacol; 2008 Dec; 74(6):1657-65. PubMed ID: 18794327
[TBL] [Abstract][Full Text] [Related]
5. Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours.
Hussein D; Holt SV; Brookes KE; Klymenko T; Adamski JK; Hogg A; Estlin EJ; Ward T; Dive C; Makin GW
Br J Cancer; 2009 Jul; 101(1):55-63. PubMed ID: 19491903
[TBL] [Abstract][Full Text] [Related]
6. Role of NADPH cytochrome P450 reductase in activation of RH1.
Begleiter A; Leith MK; Patel D; Hasinoff BB
Cancer Chemother Pharmacol; 2007 Oct; 60(5):713-23. PubMed ID: 17256129
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice.
Loadman PM; Phillips RM; Lim LE; Bibby MC
Biochem Pharmacol; 2000 Apr; 59(7):831-7. PubMed ID: 10718341
[TBL] [Abstract][Full Text] [Related]
8. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
[TBL] [Abstract][Full Text] [Related]
9. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
Winski SL; Hargreaves RH; Butler J; Ross D
Clin Cancer Res; 1998 Dec; 4(12):3083-8. PubMed ID: 9865924
[TBL] [Abstract][Full Text] [Related]
10. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1.
Dehn DL; Winski SL; Ross D
Clin Cancer Res; 2004 May; 10(9):3147-55. PubMed ID: 15131056
[TBL] [Abstract][Full Text] [Related]
11. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones.
Winski SL; Swann E; Hargreaves RH; Dehn DL; Butler J; Moody CJ; Ross D
Biochem Pharmacol; 2001 Jun; 61(12):1509-16. PubMed ID: 11377380
[TBL] [Abstract][Full Text] [Related]
12. [DT-diaphorase].
Mikami K; Shirakusa T; Tsuruo T
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1606-10. PubMed ID: 9309161
[TBL] [Abstract][Full Text] [Related]
13. Effect of NQO1 induction on the antitumor activity of RH1 in human tumors in vitro and in vivo.
Digby T; Leith MK; Thliveris JA; Begleiter A
Cancer Chemother Pharmacol; 2005 Sep; 56(3):307-16. PubMed ID: 15877230
[TBL] [Abstract][Full Text] [Related]
14. The anti-tumour compound, RH1, causes mitochondria-mediated apoptosis by activating c-Jun N-terminal kinase.
Park MT; Song MJ; Oh ET; Lee H; Choi BH; Jeong SY; Choi EK; Park HJ
Br J Pharmacol; 2011 Jun; 163(3):567-85. PubMed ID: 21250978
[TBL] [Abstract][Full Text] [Related]
15. Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts.
Cowen RL; Patterson AV; Telfer BA; Airley RE; Hobbs S; Phillips RM; Jaffar M; Stratford IJ; Williams KJ
Mol Cancer Ther; 2003 Sep; 2(9):901-9. PubMed ID: 14555709
[TBL] [Abstract][Full Text] [Related]
16. The reductive activation of the antitumor drug RH1 to its semiquinone free radical by NADPH cytochrome P450 reductase and by HCT116 human colon cancer cells.
Hasinoff BB; Begleiter A
Free Radic Res; 2006 Sep; 40(9):974-8. PubMed ID: 17015278
[TBL] [Abstract][Full Text] [Related]
17. DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9.
Plumb JA; Gerritsen M; Workman P
Br J Cancer; 1994 Dec; 70(6):1136-43. PubMed ID: 7526885
[TBL] [Abstract][Full Text] [Related]
18. Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1.
Danson SJ; Johnson P; Ward TH; Dawson M; Denneny O; Dickinson G; Aarons L; Watson A; Jowle D; Cummings J; Robson L; Halbert G; Dive C; Ranson M
Ann Oncol; 2011 Jul; 22(7):1653-1660. PubMed ID: 21378203
[TBL] [Abstract][Full Text] [Related]
19. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9.
Fitzsimmons SA; Workman P; Grever M; Paull K; Camalier R; Lewis AD
J Natl Cancer Inst; 1996 Mar; 88(5):259-69. PubMed ID: 8614004
[TBL] [Abstract][Full Text] [Related]
20. DT-diaphorase: a target for new anticancer drugs.
Danson S; Ward TH; Butler J; Ranson M
Cancer Treat Rev; 2004 Aug; 30(5):437-49. PubMed ID: 15245776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]